


CLAIMS

What is claimed is:

1. A compound of formula (I)



wherein:

R¹ and R² are each independently hydrogen, deuterium, halo, hydroxyl, NH₂, aryl, heteroaryl, or optionally substituted C₁₋₄ alkyl,

wherein said C₁₋₄ alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, and NH₂;

R^{3a} is hydrogen, deuterium, C₁₋₆ alkyl, phenyl, or benzyl and

R^{3b} is hydrogen, deuterium, or C₁₋₆ alkyl; or

R^{3a} and R^{3b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are each optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl;

R^{4a} is hydrogen, C₁₋₆ alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,

wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C₁₋₄ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, -COOR^b, -SO₂R^b, -NHC(O)R^b, and -NR^bR^b and

R^{4b} is hydrogen, deuterium, or C₁₋₃ alkyl; or

R^{4a} and R^{4b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl,

provided that only one of R^{3a} and R^{3b} and R^{4a} and R^{4b} are joined together forming a ring;

R^{5a} is hydrogen or deuterium;


R^{5b} is hydrogen, deuterium, methyl, ethyl, CD₃, CF₃, CH₂F, or CHF₂ and

R⁶ is optionally substituted C₁₋₆ alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C₃₋₁₀ cycloalkyl,

wherein said C₁₋₆ alkyl is optionally substituted with one substituent selected from the group consisting of hydroxyl, C₁₋₃ alkoxy and -OR^a,

wherein said aryl, heteroaryl, heterocyclic and C₃₋₁₀ cycloalkyl are optionally substituted with one to three substituents each independently selected from the group consisting of: halo; hydroxyl; cyano; nitro; C₁₋₄ alkoxy; C₁₋₃ haloalkyl; C₁₋₃ haloalkoxy; C₁₋₆ alkyl; C₃₋₆ cycloalkyl optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxyl, cyano, C₁₋₃ alkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkyl; phenyl optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, -COOR^b, -SO₂R^b, -NHC(O)R^b, and NR^bNR^b; 5-6 membered heteroaryl optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, C₁₋₃ alkyl, C₁₋₃ alkoxy; 5-6 membered heterocyclic optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl; -CH₂R^a; -OR^a; -C(O)R^a; -NR^aR^b; -COOR^a; -SO₂R^a; -SO₂R^b; -NHC(O)R^a; -NHC(O)R^b; -C(O)NR^aR^b; -C(O)NHR^b; and -SO₂NR^bR^b; or

R^{5b} and R^6 are joined together forming an optionally substituted C_{3-7} cycloalkyl group



or an optionally substituted group of formula (a):

wherein n is 1, 2, or 3 and

said C_{3-7} cycloalkyl and group of formula (a) are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, benzyloxy, $-COOR^b$, $-SO_2R^b$, $-NHC(O)R^b$, and $-NR^bR^b$;

each R^a is independently optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C_{3-7} cycloalkyl,


wherein said phenyl and heteroaryl are optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, and C_{1-3} alkyl,

wherein said heterocyclic is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-4} alkyl, C_{3-5} cycloalkyl, $-C(O)R^b$, and $-NR^bR^b$, and

wherein said C_{3-7} cycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, and C_{1-3} alkyl; and


each R^b is independently hydrogen or C_{1-6} alkyl; or a pharmaceutically acceptable salt thereof.

2) The compound according to claim 1 of the formula (III)



(III); or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 of the formula (IV)



(IV); or a pharmaceutically acceptable salt thereof.

5

4. The compound according to claim 3 wherein R^{3a} and R^{3b} are both hydrogen; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 wherein R^{5a} is hydrogen and R^{5b} is hydrogen, methyl, ethyl, or CF₃; or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 wherein R^{5b} is methyl; or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 6 wherein R¹ is hydrogen, fluoro or chloro and R² is hydrogen, fluoro, chloro, or methyl; or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 7 wherein R¹ and R² are both hydrogen; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8 wherein R^{4a} is hydrogen, C₁₋₆ alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,

wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, -COOR^b, -SO₂R^b, -NHC(O)R^b, and -NR^bR^b and R^{4b} is hydrogen or C₁₋₃ alkyl; or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9 wherein R^{4b} is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

11. The compound according claim 10 wherein R^{4b} is hydrogen; or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 11 R^{4a} is hydrogen, methyl, ethyl, isopropyl, phenyl, 4-fluorophenyl, 4-methoxyphenyl, biphenyl, benzyl, or pyridinyl; or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 wherein R^{4a} is isopropyl; or a pharmaceutically acceptable salt thereof.


14. The compound according to any one of claims 1-13 wherein R⁶ is methyl, C₅₋₁₀ cycloalkyl, optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1,2,4-oxadiazolyl, optionally substituted isoxazolyl, thienyl, oxazolyl, quinoliny, optionally substituted benzimidazolyl, benzthiazolyl, benzoxazolyl, tetrazolo[1,5-a]pyridinyl, imidazo[2,1-b][1,3,4]thiadiazolyl, optionally substituted piperidinyl, optionally substituted piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, optionally substituted tetrahydro-thiopyran 1,1-dioxide, 1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydro-benzo[1,4]dioxinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydro-benzothiazolyl, indolizinyl, cyclopropyl, cyclopentyl, or cyclohexyl, wherein said phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazolyl, pyrazolyl, thiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, isoxazolyl, benzimidazolyl, piperidinyl, piperazinyl, and tetrahydro-thiopyran 1,1-dioxide are each optionally substituted with one or two substituents as defined in formula (I).

15. The compound according to claim 14 wherein R^6 is optionally substituted with one or two substituents each independently selected from the group consisting of: halo; hydroxy; nitro; C_{1-4} alkoxy; C_{1-3} haloalkyl; C_{1-3} haloalkoxy; C_{1-6} alkyl; C_{3-6} cycloalkyl
- 5 optionally substituted with one substituent selected from the group consisting of: cyano, C_{1-3} alkyl, and C_{1-3} alkoxy; phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, methyl, cyano, and methoxy; and 5-6 membered heteroaryl optionally substituted with one or two methyl groups; or a pharmaceutically acceptable salt thereof.
- 10
16. The compound according to claim 15 wherein R^6 is optionally substituted 1,3,4-oxadiazolyl or optionally substituted 1,2,4-oxadiazolyl; or a pharmaceutically acceptable salt thereof.
- 15
17. The compound according to claim 14 wherein R^6 is substituted with one $-CH_2R^a$, $-C(O)R^a$, $-NHC(O)R^a$, $-NHC(O)R^b$, $-C(O)NHR^a$, $-C(O)NHR^b$, $-OR^a$, $-NR^aR^b$, $-SO_2NR^bR^b$, $-SO_2R^a$, or $-SO_2R^b$ group; or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 17 wherein R^a is
- 20 (a) phenyl optionally substituted with one or two substituents each independently selected from the group consisting of fluoro, chloro and bromo;
- (b) optionally substituted 5-6 membered heteroaryl;
- (c) C_{5-7} cycloalkyl optionally substituted with one or two substituents each independently selected from the group consisting of fluoro, hydroxy, methyl, and C_{1-3}
- 25 haloalkoxy; or
- (d) a heterocyclic group selected from the group consisting of: piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, tetrahydro-thiopyran1,1-dioxide, 1,4-diazepanyl, 4,7-diaza-spiro[2.5]octanyl, 3,8-diaza-bicyclo[3.2.1]octanyl, 3,8-diaza-bicyclo[4.2.0]octanyl, octahydro-pyrrolo[1,2-a]pyrazinyl, octahydro-pyrido[1,2-a]pyrazinyl,
- 30 octahydro-pyrrolo[3,4-c]pyrrolyl, and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazinyl each of which is optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxy, fluoro, amino, dimethylamino, C_{1-3} haloalkoxy, C_{1-3} alkyl, and C_{3-5} cycloalkyl; or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 18 wherein R⁶ is optionally substituted phenyl; or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 19 wherein the phenyl is substituted with one
5 -CH₂R^a, -C(O)R^a, or -C(O)NHR^a group in the para position; or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 2 of the formula (V)



10 wherein R^{4a} is phenyl and R^{4b} is hydrogen; or a pharmaceutically acceptable salt there

22. The compound according to claim 1 selected from the group consisting of:

(S)-4-isopropyl-3-(2-(((S)-1-(4-(2-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

N-(4-(((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-

15 yl)amino)ethyl)phenyl)cyclohexanecarboxamide;

(S)-3-(2-(((S)-1-(3-fluoro-4-((4-methylpiperazin-1-

yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-(((S)-1-(4-((3,3,4-trimethylpiperazin-1-
yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

20 2-fluoro-N-(4-hydroxy-4-methylcyclohexyl)-4-(((S)-1-((4-((S)-4-isopropyl-2-oxoxazolidin-
3-yl)pyrimidin-2-yl)amino)ethyl)benzamide;

(S)-3-(2-(((S)-1-(4-((4-amino-4-methylpiperidin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-
yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-(((S)-1-(4-((4-(dimethylamino)piperidin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-
25 4-yl)-4-isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-(((S)-1-(4-((4-methylpiperazin-1-
yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-4-isopropyl-4-methyl-3-(2-(((S)-1-(4-((4-methylpiperazin-1-
yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

30 (S)-4-isopropyl-3-(2-(((S)-1-(6-phenylpyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-
one;

- (S)-3-(2-((S)-1-(4-benzoylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-4-isopropyl-3-(2-(((S)-1-(5-phenyl-1,3,4-thiadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
(4S)-4-isopropyl-3-(2-(1-(5-phenylpyrimidin-2-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;
5 3-(5-fluoro-2-((1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
(S)-4-isopropyl-3-(2-(((S)-1-(1-(3-methoxyphenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
10 (S)-3-(2-(((S)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-4-isopropyl-3-(2-(((S)-1-(3-(m-tolyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
15 (S)-3-(2-(((S)-1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(2-((S)-1-(5-(4-fluoro-2-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
20 (S)-4-isopropyl-3-(2-[(3-p-tolyl-[1,2,4]oxadiazol-5-yl)methyl]-amino)-pyrimidin-4-yl)-oxazolidin-2-one;
(S)-4-isopropyl-3-(2-((S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;
(S)-3-(2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
25 (S)-3-(2-((S)-1-(4-isobutoxy-3-methylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
30 (S)-3-(5-fluoro-2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;
(S)-3-(5-fluoro-2-((S)-1-(3-fluoro-4-(piperidine-1-carbonyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
35 N-cyclohexyl-2-fluoro-4-((S)-1-(5-fluoro-4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;

N-cyclohexyl-2-fluoro-4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide; and

(S)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

5

23. The compound according to claim 1 selected from the group consisting of:

(S)-3-(2-(((S)-1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-

yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-(((S)-1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-

10 4-isopropylloxazolidin-2-one;

(S)-3-(5-fluoro-2-(1-(4-phenoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-3-(2-((S)-1-(4-(4-fluorophenoxy)phenyl)ethylamino)pyrimidin-4-yl)-4-

isopropylloxazolidin-2-one;

(S)-3-(2-((S)-1-(4-(((2S,6R)-2,6-dimethylmorpholino)methyl)phenyl)ethylamino)pyrimidin-

15 4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-(((S)-1-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

20 (S)-3-(2-((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-((S)-1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-((S)-1-(5-(4-fluorophenoxy)pyrazin-2-yl)ethylamino)pyrimidin-4-yl)-4-

25 isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one; and

(S)-3-(2-((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

30

24. The compound according to claim 1 selected from the group consisting of:

(S)-3-(2-(1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-5-fluoropyrimidin-4-yl)-4,4-dimethylloxazolidin-2-one;

(S)-3-(6-chloro-2-(1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

35

(S)-3-(2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

- (S)-3-(2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
2-chloro-N-cyclopentyl-4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;
- 5 (S)-3-(2-((S)-1-(4-((3,3-difluoropiperidin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(2-((S)-1-(4-(4,7-diazaspiro[2.5]octan-4-ylmethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(2-((S)-1-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-
- 10 isopropylloxazolidin-2-one;
(S)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
(S)-3-(5-fluoro-2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one; and
- 15 2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide; or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 1, wherein

each R^1 and R^2 is independently hydrogen, deuterium, halo, hydroxyl, NH_2 , aryl, heteroaryl, or optionally substituted C_{1-4} alkyl,

wherein said C_{1-4} alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, and NH_2 ;

R^{3a} is hydrogen, deuterium, C_{1-6} alkyl, phenyl, or benzyl and

R^{3b} is hydrogen, deuterium, or C_{1-6} alkyl; or

R^{3a} and R^{3b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are each optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl;

R^{4a} is hydrogen, C_{1-6} alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,

wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents each independently selected from the group consisting of:

halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, COOR^b, SO₂R^b, NHC(O)R^b, and NR^bR^b and

R^{4b} is hydrogen, deuterium, or C₁₋₃ alkyl; or

R^{4a} and R^{4b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl,

provided that only one of R^{3a} and R^{3b} and R^{4a} and R^{4b} are joined together forming a ring;

R^{5a} is hydrogen or deuterium;


R^{5b} is hydrogen, deuterium, methyl, ethyl, CF₃, CF₃, CH₂F, or CHF₂ and

R⁶ is optionally substituted C₁₋₆ alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C₅₋₁₀ cycloalkyl,

wherein said C₁₋₆ alkyl is optionally substituted with one substituent selected from the group consisting of hydroxyl, C₁₋₃ alkoxy and -OR^a;

wherein said aryl, heteroaryl, heterocyclic and C₅₋₁₀ cycloalkyl are optionally substituted with one to three substituents each independently selected from the group consisting of: halo; hydroxyl; cyano; nitro; C₁₋₃ alkoxy; C₁₋₃ haloalkyl; C₁₋₃ haloalkoxy; C₁₋₆ alkyl; C₃₋₆ cycloalkyl; phenyl optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, COOR^b, SO₂R^b, NHC(O)R^b, and NR^bR^b; 5-6 membered heteroaryl; 5-6 membered heterocyclic optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl; -CH₂R^a; -OR^a; -C(O)R^a; -NR^aR^b; -COOR^a; -SO₂R^a; NHC(O)R^a; and -SO₂NR^bR^b; or

R^{5b} and R⁶ are joined together forming an optionally substituted C₃₋₇ cycloalkyl group



or an optionally substituted group of formula (a):

wherein n is 1, 2, or 3 and

said C₃₋₇ cycloalkyl and group of formula (a) are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, benzyloxy, COOR^b, SO₂R^b, NHC(O)R^b, and NR^bR^b;

each R^a is independently optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted 4-7 membered heterocyclic,

wherein said phenyl and heteroaryl are optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl,

wherein said 4-7 membered heterocyclic is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl; and

each R^b is independently hydrogen or C₁₋₆ alkyl; or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 25 wherein

R¹ is hydrogen, fluoro, chloro, or methyl;

R² is hydrogen;

R^{3a} is hydrogen, methyl, or phenyl;

R^{3b} is hydrogen or methyl;

R^{4a} is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene;

R^{4b} is hydrogen or methyl;

R^{5a} is H; and

R^{5b} is hydrogen, methyl, ethyl, or CF₃; or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 26 wherein wherein R⁶ is isopropyl, optionally substituted aryl, optionally substituted pyrazolyl, optionally substituted pyridinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or optionally substituted C₅₋₁₀ cycloalkyl; or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.


29. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to subject in need of thereof.

30. A method for the treatment of a disease or disorder associated with a mutant IDH protein having a neomorphic activity comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and another therapeutic agent to subject in need of thereof.

What is claimed is:

1. A compound of formula (I)

(I)



wherein:

R^1 and R^2 are each independently hydrogen, deuterium, halo, hydroxyl, NH_2 , aryl, heteroaryl, or optionally substituted C_{1-4} alkyl,

wherein said C_{1-4} alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, and NH_2 ;

R^{3a} is hydrogen, deuterium, C_{1-6} alkyl, phenyl, or benzyl and

R^{3b} is hydrogen, deuterium, or C_{1-6} alkyl; or

R^{3a} and R^{3b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are each optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl;

R^{4a} is hydrogen, C_{1-6} alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,

wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents

30 each independently selected from the group consist-
 ing of: halo, hydroxyl, cyano, nitro, C₁₋₄ alkoxy, C₁₋₃
 haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆
 cycloalkyl, phenyl, 5-6 membered heteroaryl, 5-6
 35 membered heterocyclic, phenoxy, —COOR^b,
 —SO₂R^b, —NHC(O)R^b, and —NR^bR^b and

R^{4b} is hydrogen, deuterium, or C₁₋₃ alkyl; or

R^{4a} and R^{4b} are joined together forming an optionally sub-
 stituted 3-7 membered cycloalkyl ring or an optionally
 40 substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are
 optionally substituted with one or two substituents
 each independently selected from the group consist-
 ing of: halo, hydroxyl, oxo, NH₂, and C₁₋₃ alkyl,

45 provided that only one of R^{3a} and R^{3b} and R^{4a} and R^{4b}
 are joined together forming a ring;

R^{5a} is hydrogen or deuterium;


R^{5b} is hydrogen, deuterium, methyl, ethyl, CD₃, CF₃,
 CH₂F, or CHF₂ and

50 R⁶ is optionally substituted C₁₋₆ alkyl, optionally substi-
 tuted aryl, optionally substituted heteroaryl, optionally
 substituted heterocyclic, or optionally substituted C₃₋₁₀
 cycloalkyl,

wherein said C₁₋₆ alkyl is optionally substituted with one
 55 substituent selected from the group consisting of
 hydroxyl, C₁₋₃ alkoxy and —OR^a,

wherein said aryl, heteroaryl, heterocyclic and C₃₋₁₀
 cycloalkyl are optionally substituted with one to three
 substituents each independently selected from the
 60 group consisting of: halo; hydroxyl; cyano; nitro; C₁₋₄
 alkoxy; C₁₋₃ haloalkyl; C₁₋₃ haloalkoxy; C₁₋₆ alkyl;
 C₃₋₆ cycloalkyl optionally substituted with one to
 three substituents each independently selected from
 the group consisting of: hydroxyl, cyano, C₁₋₃ alkyl,
 65 C₁₋₃ alkoxy, and C₁₋₃ haloalkyl; phenyl optionally
 substituted with one to three substituents each inde-
 pendently selected from the group consisting of: halo,

hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, $-\text{COOR}^b$, $-\text{SO}_2\text{R}^b$, $-\text{NHC}(\text{O})\text{R}^b$, and NR^bR^b ; 5-6 membered heteroaryl optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, C_{1-3} alkyl, C_{1-3} alkoxy; 5-6 membered heterocyclic optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl; $-\text{CH}_2\text{R}^a$; $-\text{OR}^a$; $-\text{C}(\text{O})\text{R}^a$; $-\text{NR}^a\text{R}^b$; $-\text{COOR}^a$; $-\text{SO}_2\text{R}^a$; $-\text{SO}_2\text{R}^b$; $-\text{NHC}(\text{O})\text{R}^a$; $-\text{NHC}(\text{O})\text{R}^b$; $-\text{C}(\text{O})\text{NR}^a\text{R}^b$; $-\text{C}(\text{O})\text{NHR}^b$; and $-\text{SO}_2\text{NR}^b\text{R}^b$; or R^{5b} and R^6 are joined together forming an optionally substituted C_{3-7} cycloalkyl group or an optionally substituted group of formula (a):



(a)

wherein n is 1, 2, or 3 and

said C_{3-7} cycloalkyl and group of formula (a) are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, benzyloxy, $-\text{COOR}^b$, $-\text{SO}_2\text{R}^b$, $-\text{NHC}(\text{O})\text{R}^b$, and $-\text{NR}^b\text{R}^b$;

each R^a is independently optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C_{3-7} cycloalkyl,

wherein said phenyl and heteroaryl are optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, and C_{1-3} alkyl,


wherein said heterocyclic is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-4} alkyl, C_{3-5} cycloalkyl, $-\text{C}(\text{O})\text{R}^b$, and $-\text{NR}^b\text{R}^b$, and

wherein said C_{3-7} cycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, and C_{1-3} alkyl; and

each R^b is independently hydrogen or C_{1-6} alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 of the formula (III)


(III)



or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 of the formula (IV)

(IV)



or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 3 wherein R^{3a} and R^{3b} are both hydrogen; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 wherein R^{5a} is hydrogen and R^{5b} is hydrogen, methyl, ethyl, or CF_3 ; or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 wherein R^{5b} is methyl; or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 6 wherein R^1 is hydrogen, fluoro or chloro and R^2 is hydrogen, fluoro, chloro, or methyl; or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 7 wherein R^1 and R^2 are both hydrogen; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8 wherein R^{4a} is hydrogen, C_{1-6} alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,

wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, $-COOR^b$, $-SO_2R^b$, $-NHC(O)R^b$, and $-NR^bR^b$ and R^{4b} is hydrogen or C_{1-3} alkyl; or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9 wherein R^{4b} is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

11. The compound according claim 10 wherein R^{4b} is hydrogen; or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 11 R^{4a} is hydrogen, methyl, ethyl, isopropyl, phenyl, 4-fluorophenyl, 4-methoxyphenyl, biphenyl, benzyl, or pyridinyl; or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 wherein R^{4a} is isopropyl; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 wherein R^6 is methyl, C_{5-10} cycloalkyl, optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted 1,2,4-oxadiazolyl, optionally substituted isoxazolyl, thienyl, oxazolyl, quinolinyl, optionally substituted benzimidazolyl, benzthiazolyl, benzoxazolyl, tetrazolo[1,5-a]pyridinyl, imidazo[2,1-b][1,3,4]thiadiazolyl, optionally substituted piperidinyl, optionally substituted piperazinyl, tetrahydrofuranlyl, tetrahydropyranyl, optionally substituted tetrahydrothiopyran-1,1-dioxide, 1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydro-benzo[1,4]dioxinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydro-benzothiazolyl, indolizinyl, cyclopropyl, cyclopentyl, or cyclohexyl, wherein said phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazolyl, pyrazolyl, thiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, isoxazolyl, benzimidazolyl, piperidinyl, piperazinyl, and tetrahydro-thiopyran-1,1-dioxide are each optionally substituted with one or two substituents as defined in formula (I).

15. The compound according to claim 14 wherein R^6 is optionally substituted with one or two substituents each independently selected from the group consisting of: halo; hydroxy; nitro; C_{1-4} alkoxy; C_{1-3} haloalkyl; C_{1-3} haloalkoxy; C_{1-6} alkyl; C_{3-6} cycloalkyl optionally substituted with one substituent selected from the group consisting of: cyano, C_{1-3} alkyl, and C_{1-3} alkoxy; phenyl optionally substituted with one or two substituents each independently selected from the group consisting of: fluoro, chloro, methyl, cyano, and methoxy; and 5-6 membered heteroaryl optionally substituted with one or two methyl groups; or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 15 wherein R^6 is optionally substituted 1,3,4-oxadiazolyl or optionally substituted 1,2,4-oxadiazolyl; or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 14 wherein R^6 is substituted with one $-\text{CH}_2R^a$, $-\text{C}(\text{O})R^a$, $-\text{NHC}(\text{O})R^a$, $-\text{NHC}(\text{O})R^b$, $-\text{C}(\text{O})\text{NHR}^a$, $\text{C}(\text{O})\text{NHR}^b$, $-\text{OR}^a$, $-\text{NR}^aR^b$, $-\text{SO}_2\text{NR}^bR^b$, $-\text{SO}_2R^a$, or $-\text{SO}_2R^b$ group; or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 17 wherein R^a is

(a) phenyl optionally substituted with one or two substituents each independently selected from the group consisting of fluoro, chloro and bromo;

(b) optionally substituted 5-6 membered heteroaryl;

(c) C_{5-7} cycloalkyl optionally substituted with one or two substituents each independently selected from the group consisting of fluoro, hydroxy, methyl, and C_{1-3} haloalkoxy; or

(d) a heterocyclic group selected from the group consisting of: piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, tetrahydro-thiopyran-1,1-dioxide, 1,4-diazepanyl, 4,7-diaza-spiro[2.5]octanyl, 3,8-diaza-bicyclo[3.2.1]octanyl, 3,8-diaza-bicyclo[4.2.0]octanyl, octahydro-pyrrolo[1,2-a]pyrazinyl, octahydro-pyrrolo[1,2-a]pyrazinyl, octahydro-pyrrolo[3,4-c]pyrrolyl, and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazinyl each of which is optionally substituted with one to three substituents each independently selected from the group consisting of: hydroxy, fluoro, amino, dimethylamino, C_{1-3}


haloalkoxy, C₁₋₃ alkyl, and C₃₋₅ cycloalkyl; or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 18 wherein R⁶ is optionally substituted phenyl; or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 19 wherein the phenyl is substituted with one —CH₂R^a, —C(O)R^a, or —C(O)NHR^a group in the para position; or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 2 of the formula (V)

(V)



wherein R^{4a} is phenyl and R^{4b} is hydrogen; or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1 selected from the group consisting of:

(S)-4-isopropyl-3-(2-(((S)-1-(4-(2-yl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

N-(4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)phenyl)cyclohexanecarboxamide;

(S)-3-(2-(((S)-1-(3-fluoro-4-((4-methylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-(((S)-1-(4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

2-fluoro-N-(4-hydroxy-4-methylcyclohexyl)-4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzamide;

(S)-3-(2-((S)-1-(4-((4-amino-4-methylpiperidin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-3-(2-((S)-1-(4-((4-(dimethylamino)piperidin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-((S)-1-(4-((4-methylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-4-isopropyl-4-methyl-3-(2-((S)-1-(4-((4-methylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-4-isopropyl-3-(2-((S)-1-(6-phenylpyridin-3-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-3-(2-((S)-1-(4-benzoylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

(S)-4-isopropyl-3-(2-(((S)-1-(5-phenyl-1,3,4-thiadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(4S)-4-isopropyl-3-(2-(1-(5-phenylpyrimidin-2-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;

3-(5-fluoro-2-((1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

(S)-4-isopropyl-3-(2-(((S)-1-(1-(3-methoxyphenyl)-1H-pyrazol-4-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;

- (S)-3-(2-(((S)-1-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-4-isopropyl-3-(2-(((S)-1-(3-(m-tolyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one;
- (S)-3-(2-(((S)-1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(5-(4-fluoro-2-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-4-isopropyl-3-{2-[(3-p-tolyl-[1,2,4]oxadiazol-5-ylmethyl)-amino]-pyrimidin-4-yl}-oxazolidin-2-one;
- (S)-4-isopropyl-3-(2-((S)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;
- (S)-3-(2-((S)-1-(2-fluoro-4-isopropylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(4-isobutoxy-3-methylphenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(5-fluoro-2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;
- (S)-3-(5-fluoro-2-((S)-1-(3-fluoro-4-(piperidine-1-carbonyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- N-cyclohexyl-2-fluoro-4-((S)-1-(5-fluoro-4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;
- N-cyclohexyl-2-fluoro-4-((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide; and
- (S)-3-(5-fluoro-2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one; or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 1 selected from the group consisting of:

- (S)-3-(2-(((S)-1-(3-fluoro-4-((3,3,4-trimethylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-(((S)-1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(5-fluoro-2-(1-(4-phenoxyphenyl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;
- (S)-3-(2-((S)-1-(4-(4-fluorophenoxy)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(4-(((2S,6R)-2,6-dimethylmorpholino)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-(((S)-1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-(((S)-1-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(5-(4-fluoro-3-methylphenyl)pyridin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;

- (S)-3-(2-((S)-1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 5 (S)-3-(2-((S)-1-(5-(4-fluorophenoxy)pyrazin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-4-isopropyl-3-(2-((S)-1-(5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one; and
- 10 (S)-3-(2-((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one; or a pharmaceutically acceptable salt thereof.
24. The compound according to claim 1 selected from the group consisting of:
- 15 (S)-3-(2-(1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)-5-fluoropyrimidin-4-yl)-4,4-dimethylloxazolidin-2-one;
- (S)-3-(6-chloro-2-(1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one;
- 20 (S)-3-(2-((S)-1-(2-fluoro-4-(1-methylcyclopropyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 25 2-chloro-N-cyclopentyl-4-((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide;
- (S)-3-(2-((S)-1-(4-((3,3-difluoropiperidin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 30 (S)-3-(2-((S)-1-(4-(4,7-diazaspiro[2.5]octan-4-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(2-((S)-1-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 35 (S)-3-(2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- (S)-3-(5-fluoro-2-(((S)-1-(4-isobutoxyphenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropylloxazolidin-2-one;
- 40 and
- 2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-((S)-1-(4-((S)-4-isopropyl-2-oxoxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzamide; or a pharmaceutically acceptable salt thereof.
- 45 25. The compound according to claim 1 wherein each R^1 and R^2 is independently hydrogen, deuterium, halo, hydroxyl, NH_2 , aryl, heteroaryl, or optionally substituted C_{1-4} alkyl,
- 50 wherein said C_{1-4} alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, and NH_2 ;
- R^{3a} is hydrogen, deuterium, C_{1-6} alkyl, phenyl, or benzyl and
- 55 R^{3b} is hydrogen, deuterium, or C_{1-6} alkyl; or
- R^{3a} and R^{3b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,
- 60 wherein said cycloalkyl and heterocyclic rings are each optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl;
- R^{4a} is hydrogen, C_{1-6} alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,
- 65 wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents

each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, $COOR^b$, SO_2R^b , $NHC(O)R^b$, and NR^bR^b and

R^{4b} is hydrogen, deuterium, or C_{1-3} alkyl; or

R^{4a} and R^{4b} are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,

wherein said cycloalkyl and heterocyclic rings are optionally substituted with one or two substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl,

provided that only one of R^{3a} and R^{3b} and R^{4a} and R^{4b} are joined together forming a ring;

R^{5a} is hydrogen or deuterium;

R^{5b} is hydrogen, deuterium, methyl, ethyl, CD_3 , CF_3 , CH_2F , or CHF_2 and


R^6 is optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C_{5-10} cycloalkyl,

wherein said C_{1-6} alkyl is optionally substituted with one substituent selected from the group consisting of hydroxyl, C_{1-3} alkoxy and $-OR^a$;

wherein said aryl, heteroaryl, heterocyclic and C_{5-10} cycloalkyl are optionally substituted with one to three substituents each independently selected from the group consisting of: halo; hydroxyl; cyano; nitro; C_{1-3} alkoxy; C_{1-3} haloalkyl; C_{1-3} haloalkoxy; C_{1-6} alkyl; C_{3-6} cycloalkyl; phenyl optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, cyano, nitro, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, $COOR^b$, SO_2R^b , $NHC(O)R^b$, and NR^bR^b ; 5-6 membered heteroaryl; 5-6 membered heterocyclic optionally substituted with one to three substituents each independently selected from the group consisting of: halo, hydroxyl, oxo, NH_2 , and C_{1-3} alkyl; $-CH_2R^a$; $-OR^a$; $-C(O)R^a$; $-NR^aR^b$; $-COOR^a$; $-SO_2R^a$; $NHC(O)R^a$; and $-SO_2NR^bR^b$; or

R^{5b} and R^6 are joined together forming an optionally substituted C_{3-7} cycloalkyl group or an optionally substituted group of formula (a):

(a)



wherein n is 1, 2, or 3 and

said C₃₋₇ cycloalkyl and group of formula (a) are optionally substituted with one to three substituents each independently selected from the group consisting of:
 5 halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, benzyloxy, COOR^b, SO₂R^b, NHC(O)
 10 R^b, and NR^bR^b;

each R^a is independently optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted 4-7 membered heterocyclic,

15 wherein said phenyl and heteroaryl are optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, cyano, nitro, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
 20 C₁₋₃ haloalkoxy, and C₁₋₃ alkyl,

wherein said 4-7 membered heterocyclic is optionally substituted with one to three substituents each independently selected from the group consisting of halo,
 25 hydroxyl, oxo, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl; and

each R^b is independently hydrogen or C₁₋₆ alkyl; or a pharmaceutically acceptable salt thereof.

30 **26.** The compound according to claim 25 wherein

R¹ is hydrogen, fluoro, chloro, or methyl;

R² is hydrogen;

35 R^{3a} is hydrogen, methyl, or phenyl;

R^{3b} is hydrogen or methyl;

R^{4a} is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene;
 40

R^{4b} is hydrogen or methyl;

R^{5a} is H; and

45 R^{5b} is hydrogen, methyl, ethyl, or CF₃; or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 26 wherein R⁶ is isopropyl, optionally substituted aryl, optionally substituted pyrazolyl, optionally substituted pyridinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or optionally substituted C₅₋₁₀ cycloalkyl; or a pharmaceutically acceptable salt thereof.
 50

28. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
 55